Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Gene expression analysis of H358 non-small cell lung cancer cells selected for resistance against erlotinib or wild-type


ABSTRACT: Erlotinib is a tyrosine kinase inhibitor (TKI) that is approved as a second-line monotherapy in patients with advanced non-small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest since overtime, many tumors develop resistance. To analyse the changes in the gene expression profile, that accompany resistance development, we treated the erlotinib sensitive non-small cell lung cancer cell line H358 with increasing concentrations of erlotinib (1-5µM) for several weeks (H358res). In parallel, we kept H358 with the same concentrations of the vehicle DMSO (H358co). After ten weeks of treatment, when the H358res stably grew under 5µM erlotinib, total RNA of both cell lines was harvested and hybridized.

ORGANISM(S): Homo sapiens

SUBMITTER: Simone Brabletz 

PROVIDER: E-MTAB-3387 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2015-09-15 | E-MTAB-3391 | biostudies-arrayexpress
2014-01-01 | E-GEOD-52308 | biostudies-arrayexpress
2018-03-21 | PXD006705 | Pride
2023-04-26 | GSE229068 | GEO
2014-09-23 | GSE58542 | GEO
2014-01-01 | GSE52308 | GEO
2022-08-31 | GSE131952 | GEO
2014-09-23 | E-GEOD-58542 | biostudies-arrayexpress
2024-02-22 | GSE249914 | GEO
2016-06-15 | E-MTAB-3479 | biostudies-arrayexpress